Denner Capital Management

Denner operates as a shareholder activist, not a passive stock picker. He acquires large stakes in biotechnology and pharmaceutical companies with the explicit goal of reshaping strategy, management, or the board. Where a traditional healthcare fund might buy a diversified basket of names and wait for clinical catalysts, Denner inserts himself into governance to force capital reallocation, asset sales, or outright company sales. This blurs the line between investment management and corporate control.

Sarissa Capital Management was the activist vehicle Alex Denner founded in 2012. Denner Capital Management represents a successor or parallel entity through which Denner now conducts his investment activities. While the exact corporate separation is not extensively detailed in public records, the strategy — concentrated activist positions in life sciences — remains continuous across both entities.

The firm's public filings and documented campaigns show a strong preference for publicly traded life sciences companies. The activist playbook relies on public-market mechanisms — proxy contests, 13D filings, and shareholder votes — to force change. There is no public evidence of meaningful private company or venture-stage investments. The mandate is built around the transparency and liquidity of public equities as the arena for governance battles.

Denner's most visible campaigns include securing board seats at Biogen, where he pushed for cost discipline and strategic focus during the company's Alzheimer's pipeline struggles, and at Amarin, where he challenged management following the Vascepa patent ruling. Earlier, at Ariad Pharmaceuticals, he opposed the company's sale price to Takeda as undervaluing the oncology asset, extracting a higher bid. At The Medicines Company, he supported the development pathway that led to its $9.7 billion sale to Novartis.

Yes, the firm files quarterly 13F holdings reports with the SEC when its US long equity portfolio exceeds $100 million in assets. These filings provide a periodic window into the firm's concentrated positions in biotechnology and pharmaceutical companies, though derivatives, short positions, and non-US holdings are not captured in 13F disclosures.